The economic burden of prostate cancer in Iran: a cross-sectional cost-of-illness study.

ABSTRACT:

Objective

This study aims to assess the economic burden of prostate cancer in Iran by analyzing direct medical costs, direct non-medical costs, and indirect costs. We conducted a cross-sectional cost-of-illness study in Khorramabad, located in western Iran, during 2023, using a prevalence-based, bottom-up approach. Data were collected from 285 prostate cancer patients using questionnaires, interviews, and patient records.

Results

Our study estimated the economic burden of prostate cancer at $744,990. Direct medical costs accounted for 63.50% of this, totaling $153,330, with therapy being the largest component. Direct non-medical costs were $62,130, and indirect costs from productivity losses were $209,760. The calculated overall cost per patient was $2,614.88. Extrapolating

SUBMITTER: Darvishi Teli B 

PROVIDER: S-EPMC11409588 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature